Table 3 The relationship between the expression of ESM1 and the clinicopathological features of OC patients.

From: IGF2BP3/ESM1/KLF10/BECN1 positive feedback loop: a novel therapeutic target in ovarian cancer via lipid metabolism reprogramming

Items

ESM1-L

ESM1-H

p-value

N

31

63

 

Age (mean ± SD)

53.46 ± 10.85

53.33 ± 8.64

0.951

T stage

  

0.3537

T1

3

8

 

T2

5

4

 

T3

23

49

 

T4

0

2

 

N stage

  

0.5893

N0

20

37

 

N1

11

26

 

M stage

  

0.319

M0

28

52

 

M1

3

11

 

FIGO stage

  

0.7381

I

3

8

 

II

4

4

 

III

18

39

 

IV

6

12

 

Methods of treatment

  

0.0869

Surgery

12

13

 

Chemotherapy

11

34

 

Surgery plus chemotherapy

4

13

 

Other

4

3

 
  1. The grouping of ESM1 high and low expression was based on the best cut-off point using X-tile. FIGO, Federation International of Gynecology and Obstetrics.
Back to article page